VYNE
VYNE Therapeutics Inc. [VYNE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VYNE Stock Summary
Top 10 Correlated ETFs
VYNE
Top 10 Correlated Stocks
VYNE
In the News
VYNE Financial details
Company Rating
Neutral
Market Cap
39.05M
Income
-28.45M
Revenue
424K
Book val./share
2.86
Cash/share
3.01
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.25
Forward P/E
-
PEG
0.07
P/S
89.5
P/B
0.65
P/C
0.76
P/FCF
-1.32
Quick Ratio
2.43
Current Ratio
2.72
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
-7.01
EPS next Y
-
EPS next Q
-
EPS this Y
-73.99%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-54.96%
Revenue last 5Y
-0.87%
Revenue Q/Q
-33.33%
EPS Q/Q
-90.05%
-
-
-
-
SMA20
50%
SMA50
50%
SMA100
-25%
Inst Own
0.72%
Inst Trans
0.99%
ROA
-156%
ROE
-139%
ROC
-2.37%
Gross Margin
100%
Oper. Margin
-8591%
Profit Margin
-8482%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.67-8.73
52W High
-71.38%
52W Low
+129%
RSI
42
Rel Volume
0.13
Avg Volume
108.25K
Volume
13.85K
Perf Week
-23.67%
Perf Month
1.78%
Perf Quarter
2%
Perf Half Y
-20.21%
-
-
-
-
Beta
1.464
-
-
Volatility
0.16%, 0.37%
Prev Close
-0.43%
Price
2.29
Change
-4.18%
VYNE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.94 | 11.66 | 5.16 | 0.15 | 0.04 | |
| Net income per share | -149.48 | -141.9 | -25.65 | -10.65 | -2.77 | |
| Operating cash flow per share | -138.1 | -76.11 | -19.72 | -9.17 | -2.47 | |
| Free cash flow per share | -138.13 | -76.18 | -19.72 | -9.17 | -2.47 | |
| Cash per share | 163.23 | 32.53 | 14.78 | 9.7 | 9.08 | |
| Book value per share | 145.33 | 20.82 | 17.01 | 9.79 | 8.64 | |
| Tangible book value per share | 145.33 | 20.82 | 17.01 | 9.79 | 8.64 | |
| Share holders equity per share | 145.33 | 20.82 | 17.01 | 9.79 | 8.64 | |
| Interest debt per share | 76.29 | 21.75 | 2.08 | -3.5 | 0.02 | |
| Market cap | 157.48M | 204.88M | 52.49M | 8.6M | 23.94M | |
| Enterprise value | 127.4M | 182.1M | 10.59M | -22.65M | -6.52M | |
| P/E ratio | -2.23 | -0.8 | -0.72 | -0.25 | -0.84 | |
| Price to sales ratio | 355.49 | 9.76 | 3.56 | 18.03 | 56.45 | |
| POCF ratio | -2.42 | -1.49 | -0.93 | -0.29 | -0.94 | |
| PFCF ratio | -2.42 | -1.49 | -0.93 | -0.29 | -0.94 | |
| P/B Ratio | 2.3 | 5.46 | 1.08 | 0.28 | 0.27 | |
| PTB ratio | 2.3 | 5.46 | 1.08 | 0.28 | 0.27 | |
| EV to sales | 287.59 | 8.67 | 0.72 | -47.49 | -15.39 | |
| Enterprise value over EBITDA | -1.67 | -1.63 | -0.16 | 0.67 | 0.22 | |
| EV to operating cash flow | -1.96 | -1.33 | -0.19 | 0.78 | 0.26 | |
| EV to free cash flow | -1.96 | -1.33 | -0.19 | 0.78 | 0.26 | |
| Earnings yield | -0.45 | -1.25 | -1.4 | -3.95 | -1.19 | |
| Free cash flow yield | -0.41 | -0.67 | -1.07 | -3.39 | -1.06 | |
| Debt to equity | 0.49 | 0.93 | 0.01 | -0.01 | 0 | |
| Debt to assets | 0.42 | 0.37 | 0.01 | -0.01 | 0 | |
| Net debt to EBITDA | 0.39 | 0.2 | 0.61 | 0.92 | 1.04 | |
| Current ratio | 7.35 | 4.07 | 3.43 | 4.1 | 12.73 | |
| Interest coverage | -30.03 | -25.85 | -12.13 | 3.17 | 0 | |
| Income quality | 0.88 | 0.54 | 0.77 | 1.26 | 0.91 | |
| Dividend Yield | 0.22 | 0 | 0.01 | 0 | 0 | |
| Payout ratio | -0.48 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 50.75 | 0 | 0 | 34.35 | 31.54 | |
| Research and developement to revenue | 121.36 | 2.07 | 1.69 | 38.54 | 38.46 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.02 | -0.01 | 0 | 0 | 0 | |
| Capex to depreciation | -0.02 | -0.33 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 15.13 | 0.86 | 0.55 | 9.01 | 7.79 | |
| Graham number | 699.14 | 257.81 | 99.08 | 48.45 | 23.2 | |
| ROIC | -0.71 | -1.53 | -1.37 | -1.12 | -0.34 | |
| Return on tangible assets | -0.89 | -2.73 | -1.09 | -0.83 | -0.29 | |
| Graham Net | 142.27 | 9.94 | 11.6 | 7.93 | 8.21 | |
| Working capital | 67.67M | 65.81M | 44.78M | 28.93M | 88.43M | |
| Tangible asset value | 68.51M | 37.49M | 48.64M | 31.2M | 88.74M | |
| Net current asset value | 67.67M | 31.01M | 44.78M | 28.72M | 87.01M | |
| Invested capital | 0.49 | 0.93 | 0.01 | -0.01 | 0 | |
| Average receivables | 67.5K | 7.98M | 11.7M | 6.38M | 2.59M | |
| Average payables | 3.53M | 4.28M | 5.65M | 4.45M | 2.02M | |
| Average inventory | 678K | 4.38M | 7.35M | 3.69M | 48.5K | |
| Days sales outstanding | 111.23 | 275.04 | 187.58 | 3.96K | 0 | |
| Days payables outstanding | 3.93K | 1.25K | 709.72 | 0 | 0 | |
| Days of inventory on hand | 1.41K | 1.94K | 794.87 | 0 | 0 | |
| Receivables turnover | 3.28 | 1.33 | 1.95 | 0.09 | 0 | |
| Payables turnover | 0.09 | 0.29 | 0.51 | 0 | 0 | |
| Inventory turnover | 0.26 | 0.19 | 0.46 | 0 | 0 | |
| ROE | -1.03 | -6.82 | -1.51 | -1.09 | -0.32 | |
| Capex per share | -0.02 | -0.06 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.03 | 0.04 | 0.03 | 0 | |
| Net income per share | -2.6 | -1.73 | -3.07 | -2.01 | -0.2 | |
| Operating cash flow per share | -1.3 | -1.68 | -2.92 | -1.57 | -0.17 | |
| Free cash flow per share | -1.3 | -1.68 | -2.92 | -1.57 | -0.17 | |
| Cash per share | 10.35 | 9.28 | 6.3 | 4.71 | 3.01 | |
| Book value per share | 10.45 | 8.12 | 5.28 | 3.51 | 2.86 | |
| Tangible book value per share | 10.45 | 8.12 | 5.28 | 3.51 | 2.86 | |
| Share holders equity per share | 10.45 | 8.12 | 5.28 | 3.51 | 2.86 | |
| Interest debt per share | 0.67 | -0.08 | 0 | 0 | 0.02 | |
| Market cap | 8.06M | 10.03M | 13.42M | 13.26M | 72.35M | |
| Enterprise value | -23.2M | -20.19M | -7.21M | -2.19M | 41.89M | |
| P/E ratio | -0.26 | -0.45 | -0.33 | -0.5 | -2.92 | |
| Price to sales ratio | 1.34K | 101.27 | 99.43 | 116.31 | 951.93 | |
| POCF ratio | -2.08 | -1.83 | -1.4 | -2.57 | -14.08 | |
| PFCF ratio | -2.08 | -1.83 | -1.4 | -2.57 | -14.08 | |
| P/B Ratio | 0.26 | 0.38 | 0.78 | 1.15 | 0.82 | |
| PTB ratio | 0.26 | 0.38 | 0.78 | 1.15 | 0.82 | |
| EV to sales | -3.87K | -203.92 | -53.41 | -19.2 | 551.14 | |
| Enterprise value over EBITDA | 2.99 | 3.44 | 0.7 | 0.35 | -6.13 | |
| EV to operating cash flow | 5.99 | 3.69 | 0.75 | 0.42 | -8.15 | |
| EV to free cash flow | 5.99 | 3.69 | 0.75 | 0.42 | -8.15 | |
| Earnings yield | -0.96 | -0.56 | -0.75 | -0.5 | -0.09 | |
| Free cash flow yield | -0.48 | -0.55 | -0.71 | -0.39 | -0.07 | |
| Debt to equity | -0.01 | 0 | 0 | 0 | 0 | |
| Debt to assets | -0.01 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 4.03 | 5.14 | 2 | 2.48 | 4.46 | |
| Current ratio | 4.1 | 4.39 | 3.6 | 2.72 | 12.73 | |
| Interest coverage | -3.41 | 22.34 | 0 | 0 | -25.98 | |
| Income quality | 0.39 | 0.97 | 0.95 | 0.78 | 0.84 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 175.99 | |
| Research and developement to revenue | 713.17 | 27.62 | 53.58 | 29.11 | 39.78 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 177.83 | 8.65 | 6.49 | 7.57 | 9.34 | |
| Graham number | 24.73 | 17.76 | 19.1 | 12.58 | 3.58 | |
| ROIC | -0.26 | -0.22 | -0.6 | -0.59 | -0.08 | |
| Return on tangible assets | -0.19 | -0.16 | -0.4 | -0.34 | -0.06 | |
| Graham Net | 8.47 | 6.59 | 4.02 | 2.41 | 2.72 | |
| Working capital | 28.93M | 25.5M | 16.59M | 11.06M | 88.43M | |
| Tangible asset value | 31.2M | 26.43M | 17.27M | 11.51M | 88.74M | |
| Net current asset value | 28.72M | 24.19M | 15.27M | 9.75M | 87.01M | |
| Invested capital | -0.01 | 0 | 0 | 0 | 0 | |
| Average receivables | 5.32M | 2.64M | 169.5K | 242K | 125K | |
| Average payables | 2.45M | 2.3M | 1.69M | 937.5K | 1.19M | |
| Average inventory | 97K | 48.5K | 33.5K | 60.5K | 27K | |
| Days sales outstanding | 77.6K | 95.45 | 156 | 197.37 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0.94 | 0.58 | 0.46 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.25 | -0.21 | -0.58 | -0.57 | -0.07 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
VYNE Frequently Asked Questions
What is VYNE Therapeutics Inc. stock symbol ?
VYNE Therapeutics Inc. is a US stock , located in Bridgewater of Nj and trading under the symbol VYNE
What is VYNE Therapeutics Inc. stock quote today ?
VYNE Therapeutics Inc. stock price is $2.29 today.
Is VYNE Therapeutics Inc. stock public?
Yes, VYNE Therapeutics Inc. is a publicly traded company.
Company Profile
- Volume Average 108.25K
- Market Capitalization 39.05M
- Employee 10
- CEO Mr. David T. Domzalski
- Headquarters Bridgewater,NJ,US
- IPO Date 2018-01-25
-
Website
https://www.vynetherapeutics.com 
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
